Mylan has formed a global collaboration with the Indian biotech Biocon to develop and commercialise biosimilar versions of three insulin analogues: Sanofi’s Lantus® (glargine), Eli Lilly’s Humalog® (lispro) and Novo Nordisk’s NovoLog® (aspart). Together these products generated combined net sales of approximately US$11.5 B in 2012. Biocon was in need of a global partner for its biosimilar insulin programmes, which until March 2012 were licensed to Pfizer. Biocon and Mylan have an existing collaboration for the development and commercialisation of five high-value generic biologics.